

FCT: Commercialization

Drug Development Funding Strategies



Suzanne Tomlinson Director: Research Programs and Strategic Initiatives, GCC





Data from: Wouters, et.al. Estimated Research and Development Investment Needed to Bring a New Medicine to Market 2009-2018, JAMA 2020; 323 (9) 844-853

Expensive endeavor....even at early stages



| Hit→Lead | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission -> Launch | |
|----------|-------------------|---------------|--------------|-------------------|------------------------|-----------------------------|---------------------------------|
| 49/ | 146/ | 62/ | 128/ | 185/ | 235/ | 44/ | Total |
| 166 | 414 | 150 | 273 | 319 | 314 | 48 | \$873/ |
| | | | | | Aillions) | | |
| | Cost per launch r | non-capitaliz | ed/capital | | T WITHONS) | | 1,778 |
| | 49/ | 49/ 146/ | 49/ 146/ 62/ | 49/ 146/ 62/ 128/ | 49/ 146/ 62/ 128/ 185/ | 49/ 146/ 62/ 128/ 185/ 235/ | 49/ 146/ 62/ 128/ 185/ 235/ 44/ |

Data from: Paul et.al. How to Improve R&D Productivity: the Pharmaceutical Industry's Grand Challenge, Nat Rev Drug Discov. 2010; 9 (3) 203-214

Which way do I go???



Funding within academia

- Federal Funding
 - NIH
 - NSF
 - DARPA
 - DOD
 - MTEC
 - CDMRP
- State funding
 - CPRIT
 - CIRM
- Institutional
- Philanthropy
- Industry partnerships/collaborations






Often earlier

stages

academic DRUGDISCOVERY consortium


https://www.addconsortium.org/


Academic-Industry partnerships/collaborations



Paul et.al., The Current Status of Drug Disc. and Dev. As Originated in US Academia: The Influence of Industrial and Academic Collaboration on Drug Disc. and Dev., Clin Transl Sci., 2018; 11, 597-606


Academic-Industry partnerships/collaborations





Paul et.al., The Current Status of Drug Disc. and Dev. As Originated in US Academia: The Influence of Industrial and Academic Collaboration on Drug Disc. and Dev., Clin Transl Sci., 2018; 11, 597-606

Working with your Tech Transfer Office









Expensive endeavor....



What is non-dilutive funding?

Source of funding that does <u>**not</u>** require exchange of equity i.e. ownership is retained</u>

- ➢ Federal Funding → Grants
- > CPRIT
- ➢ Debt
- Awards

> Source of funding that does <u>not</u> require exchange of equity i.e. ownership is retained

➢ Federal Funding → Grants

CPRIT

> Debt

> Awards





SBIR · **STTR** America's Seed Fund[™] **POWERED BY SBA**

Fast-track NCI SBIR phase IIB (phase | & II) **Bridge Award** Phase II/ direct to Phase III Crossing the Valley of Death phase II Research & development Technology validation Commercialization stage & clinical translation Commercialization plan Use of non-SBIR/STTR Up to \$400K Follow-on funding for required funds over 6 to 12 SBIR phase II awardees Up to \$2M over from any federal agencies 2 years Expectation that applicants will secure

| | Standard award | Hard cap | Waiver cap (IC specific) |
|----------|-------------------|-----------|-----------------------------|
| Phase I | \$150,000 | \$252,131 | NCI: \$400,000 |
| Phase II | \$1.0M | ~\$1.68M | NCI: \$2.0M |


Phase I

Proof-of-

concept

months

- substantial 3rd party investor funds
- \$4 M over 3 years



SBIR·STTR America's Seed Fund™

POWERED BY SBA

| | <u>Small Business Innovation Research (SBIR)</u> | <u>S</u> mall Business Technology <u>Tr</u> ansfer. (STTR) |
|-----------------------------|--|--|
| PI employment | Small business | Small business or research institution |
| Subcontracted research | 33% in Phase 1; 50% in Phase 2 | Up to 60% |
| # participating agencies | 11 | 5 |
| Research institution | Not required | Required |
| IP allocation agreement | Not required | Required |
| Phase 1 | 6 months | 12 months |

Deadlines: April 5, September 5, and January 5 \rightarrow Award ~ 6 months after deadline

Source of funding that does <u>**not</u>** require exchange of equity i.e. ownership is retained</u>

 \succ Federal Funding \rightarrow Grants

CPRIT

> Debt

Awards



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS



Cancer Prevention & Research Institute of Texas

2007 – Texas voted in favor of \$3B in general obligation bonds to fund cancer research in Texas through the creation of the Cancer Prevention Research Institute of Texas


2019 – Texas voted to approve a constitutional amendment authorizing an additional \$3B in general obligation bonds to CPRIT





Cancer Prevention & Research Institute of Texas

\$241.9 million in Grant Funds Awarded and 107 Grants Approved in 2021



https://2021annualreport.c prit.texas.gov/highlights


27 Organizations Receiving Grants



Cancer Prevention & Research Institute of Texas


Cancer Therapeutics Training Program (CTTP)







Cancer Prevention & Research Institute of Texas



27 Organizations Receiving Grants

https://2021annualreport.c prit.texas.gov/highlights



Cancer Prevention & Research Institute of Texas

- Texas Therapeutics Company RFA
 - Up to \$20M over 3 years
 - More advanced projects typically either in P1 or within 1 year of IND/IDE
 - Can fund preclinical safety and efficacy studies, CMC, GLP safety to support INDs, P1 and P2
 - Comprehensive development plan (e.g. regulatory, CTs, commercialization)
 - Detailed business plan

• Primary Review Criteria

- Significance and Impact
- Product validation/POC
- Safety
- Preclinical strength and development to date
- Detailed business plan
- Development plan

- Competitive landscape
- Intellectual property
- Business/commercial aspects
- Management and staffing
- Production/manufacturing plan
- Clinical/regulatory plan overview



Cancer Prevention & Research Institute of Texas

- SEED Award for Product Development Research
 - Up to \$3M over 3 years
 - May be earlier stage
 - Can fund target validation, lead optimization, preliminary efficacy and safety confirmation, demonstration of manufacturability
 - Tranched funding tied to milestone achievement
 - Detailed business plan

Requirements

- Must commit to be Texas based
- 2:1 match; company must raise \$1 for every \$2 provided by CPRIT (for 1st CPRIT PD award)



Cancer Prevention & Research Institute of Texas

SEED Award for Product Development Research

- Identified a novel therapeutic, diagnostic technology, or clinical tool and shown a biological effect
- Replicated/verified the research in a second model and in a second lab
- Conducted preliminary safety and toxicology testing (in the case of therapeutic agents)
- Shown the product can be manufactured at small scale or as a prototype
- Assessed the business opportunity and organized a business plan that begins to address key issues (clinical utility, target market, financial plan, IP strategy, technical challenges, etc) and lays out a preliminary development plan (formulation, toxicology, scale up, IND-enabling studies, phase 1 clinical trials, regulatory pathway, etc).
- Established key preclinical development milestones through IND submission
- Initiated a patent application
- Established a company

What is dilutive funding?


Source of funding that <u>does</u> require exchange of equity i.e. ownership in the business

- > Angel investors
- Venture Studios
- Venture Capital
- Corporate venture






Venture Capital vs Corporate Venture Capital



Startups


What is dilutive funding?



https://www.forbes.com/sites/matthewherper/2018/03/05/in-two-months-biotech-startups-raised-more-money-than-in-all-of-2013/?sh=4e3156957be7

What is dilutive funding?





Source: GlobalData, Pharma Intelligence Center



https://www.globaldata.com/media/pharma/venture-financing-deal-value-us-headquartered-biotechsdecreased-46-q1-2022-compared-q1-2021-finds-globaldata/

Funding Careers Panel

Shahila Christi, Portal Innovations

Rima Chakrabarti, KDT Ventures

Stan Watowich, Ridgeline Therapeutics, UTMB

Michael Heffernan, Fannin Innovation Studio

